PA
STLN

Parallel Advisors’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Parallel Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-39
Closed -$139 – 3960
2025
Q4 		$139 Buy
+39
New +$145 ﹤0.01% 3534

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's STLN Position: Q1 2026 in Review

Parallel Advisors sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026, closing a stake of 39 shares — an estimated $139 sold.

Parallel Advisors first reported a position in STLN in Q4 2025 and held it in 1 quarter. The position peaked at $139 in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Parallel Advisors reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
  • Parallel Advisors sold 39 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $139.
  • Parallel Advisors first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2025 and held it in 1 quarter.
  • Parallel Advisors's Starling Oncology Institute, Inc. Common Stock position peaked at $139 in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.